BACKGROUND: The aim of this research was to study the efficacy of campath 1H in combination with low-dose tacrolimus immunosuppression for intestinal, multivisceral, and liver transplantation. METHODS: Campath 1H (0.3 mg/kg) was administered in four doses: Preoperatively, at the completion of the transplant, and on postoperative days 3 and 7. Tacrolimus levels were maintained between 5 to 10 ng/dL. Suspected or mild rejections were treated with steroids. Moderate or severe rejections were treated with OKT3. PATIENTS: We studied three groups of patients: adult recipients of intestinal or multivisceral transplants, high-risk pediatric recipients of small-bowel or multivisceral grafts, and adult liver-transplant recipients. RESULTS: Twenty-one adult intestinal recipients received 24 grafts. With follow-up of 2.4 to 16 months, 14 patients are alive and 14 grafts are functioning. Eleven high-risk pediatric intestinal recipients received 12 grafts. There were four mortalities in this group, and after a follow up of 1 to 8.5 months, four patients have not experienced a rejection episode. Five adult liver recipients received five grafts. With a follow-up of 3 to 6.2 months, all five patients are alive. There were no rejection episodes in this group, and none of them required steroid therapy. CONCLUSIONS: This immunosuppressive regimen allows for the avoidance of maintenance adjuvant-steroid treatment in the majority of our patients. Our preliminary data show a trend toward a reduction of the incidence and the severity of rejection episodes, although we need to follow-up larger numbers of patients to confirm these results.
BACKGROUND: The aim of this research was to study the efficacy of campath 1H in combination with low-dose tacrolimus immunosuppression for intestinal, multivisceral, and liver transplantation. METHODS:Campath 1H (0.3 mg/kg) was administered in four doses: Preoperatively, at the completion of the transplant, and on postoperative days 3 and 7. Tacrolimus levels were maintained between 5 to 10 ng/dL. Suspected or mild rejections were treated with steroids. Moderate or severe rejections were treated with OKT3. PATIENTS: We studied three groups of patients: adult recipients of intestinal or multivisceral transplants, high-risk pediatric recipients of small-bowel or multivisceral grafts, and adult liver-transplant recipients. RESULTS: Twenty-one adult intestinal recipients received 24 grafts. With follow-up of 2.4 to 16 months, 14 patients are alive and 14 grafts are functioning. Eleven high-risk pediatric intestinal recipients received 12 grafts. There were four mortalities in this group, and after a follow up of 1 to 8.5 months, four patients have not experienced a rejection episode. Five adult liver recipients received five grafts. With a follow-up of 3 to 6.2 months, all five patients are alive. There were no rejection episodes in this group, and none of them required steroid therapy. CONCLUSIONS: This immunosuppressive regimen allows for the avoidance of maintenance adjuvant-steroid treatment in the majority of our patients. Our preliminary data show a trend toward a reduction of the incidence and the severity of rejection episodes, although we need to follow-up larger numbers of patients to confirm these results.
Authors: Sacha A De Serres; Bechara G Mfarrej; Ciara N Magee; Fanny Benitez; Isa Ashoor; Mohamed H Sayegh; William E Harmon; Nader Najafian Journal: J Am Soc Nephrol Date: 2011-11-03 Impact factor: 10.121
Authors: Ngoc L Thai; Akhtar Khan; Kusum Tom; Deanna Blisard; Amit Basu; Henkie P Tan; Amadeo Marcos; John J Fung; Thomas E Starzl; Ron Shapiro Journal: Transplantation Date: 2006-12-27 Impact factor: 4.939
Authors: David Grant; Kareem Abu-Elmagd; Jorge Reyes; Andreas Tzakis; Alan Langnas; Thomas Fishbein; Olivier Goulet; Douglas Farmer Journal: Ann Surg Date: 2005-04 Impact factor: 12.969
Authors: Jason S Hawksworth; Chirag S Desai; Khalid M Khan; Stuart S Kaufman; Nada Yazigi; Raffaele Girlanda; Alexander Kroemer; Thomas M Fishbein; Cal S Matsumoto Journal: Am J Transplant Date: 2018-04-06 Impact factor: 8.086
Authors: Amadeo Marcos; Bijan Eghtesad; John J Fung; Paulo Fontes; Kusum Patel; Michael Devera; Wallis Marsh; Timothy Gayowski; Anthony J Demetris; Edward A Gray; Bridget Flynn; Adriana Zeevi; Noriko Murase; Thomas E Starzl Journal: Transplantation Date: 2004-10-15 Impact factor: 4.939